JP2013530993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530993A5 JP2013530993A5 JP2013516932A JP2013516932A JP2013530993A5 JP 2013530993 A5 JP2013530993 A5 JP 2013530993A5 JP 2013516932 A JP2013516932 A JP 2013516932A JP 2013516932 A JP2013516932 A JP 2013516932A JP 2013530993 A5 JP2013530993 A5 JP 2013530993A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- gly
- lys
- tyr
- neurotensin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical group OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims 64
- 229920001184 polypeptide Polymers 0.000 claims 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims 50
- 230000001225 therapeutic effect Effects 0.000 claims 38
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 34
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical group NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 22
- 150000001413 amino acids Chemical group 0.000 claims 21
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 20
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 15
- 208000002193 Pain Diseases 0.000 claims 15
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 14
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 13
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 13
- 239000003900 neurotrophic factor Substances 0.000 claims 13
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical group OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 11
- 108010069042 neurotensin-like immunoreactivity Proteins 0.000 claims 11
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims 10
- DQDBCHHEIKQPJD-ODKJCKIQSA-N (2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 DQDBCHHEIKQPJD-ODKJCKIQSA-N 0.000 claims 9
- 108010081387 neurotensin (8-13) Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 6
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010003571 Astrocytoma Diseases 0.000 claims 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 5
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 150000008574 D-amino acids Chemical group 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 claims 2
- CEZSLNCYQUFOSL-BQBZGAKWSA-N Cys-Arg-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O CEZSLNCYQUFOSL-BQBZGAKWSA-N 0.000 claims 2
- DSTWKJOBKSMVCV-UWVGGRQHSA-N Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DSTWKJOBKSMVCV-UWVGGRQHSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000000527 Germinoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 2
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- 101800001814 Neurotensin Proteins 0.000 claims 2
- 102400001103 Neurotensin Human genes 0.000 claims 2
- 229940122508 Neurotensin receptor agonist Drugs 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- GCFNFKNPCMBHNT-IRXDYDNUSA-N Phe-Tyr-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)O)N GCFNFKNPCMBHNT-IRXDYDNUSA-N 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- JJKSSJVYOVRJMZ-FXQIFTODSA-N Ser-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)CN=C(N)N JJKSSJVYOVRJMZ-FXQIFTODSA-N 0.000 claims 2
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 claims 2
- 206010043276 Teratoma Diseases 0.000 claims 2
- WJKJJGXZRHDNTN-UWVGGRQHSA-N Tyr-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 WJKJJGXZRHDNTN-UWVGGRQHSA-N 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 230000036760 body temperature Effects 0.000 claims 2
- 230000001886 ciliary effect Effects 0.000 claims 2
- 108010016616 cysteinylglycine Proteins 0.000 claims 2
- 108010069495 cysteinyltyrosine Proteins 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 229940039781 leptin Drugs 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000004058 mixed glioma Diseases 0.000 claims 2
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 108010064942 Angiopep-2 Proteins 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017999 Gastrointestinal pain Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010065016 Post-traumatic pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 150000002632 lipids Chemical group 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- -1 polyplexes Substances 0.000 claims 1
- 150000003141 primary amines Chemical class 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36130510P | 2010-07-02 | 2010-07-02 | |
| US61/361,305 | 2010-07-02 | ||
| US201161494368P | 2011-06-07 | 2011-06-07 | |
| US201161494277P | 2011-06-07 | 2011-06-07 | |
| US61/494,277 | 2011-06-07 | ||
| US61/494,368 | 2011-06-07 | ||
| PCT/CA2011/050408 WO2012000118A1 (en) | 2010-07-02 | 2011-07-04 | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013530993A JP2013530993A (ja) | 2013-08-01 |
| JP2013530993A5 true JP2013530993A5 (enExample) | 2014-08-21 |
Family
ID=45401275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516932A Pending JP2013530993A (ja) | 2010-07-02 | 2011-07-04 | 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160263236A1 (enExample) |
| EP (1) | EP2588490B1 (enExample) |
| JP (1) | JP2013530993A (enExample) |
| CN (1) | CN103080125A (enExample) |
| AU (1) | AU2011274229A1 (enExample) |
| BR (1) | BR112012033295A2 (enExample) |
| CA (1) | CA2803646A1 (enExample) |
| MX (1) | MX2013000250A (enExample) |
| RU (1) | RU2013103763A (enExample) |
| WO (1) | WO2012000118A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2260874A1 (en) | 2003-01-06 | 2010-12-15 | Angiochem Inc. | Aprotinin analogs as carriers across the blood-brain barrier |
| DK2233156T3 (da) | 2005-07-15 | 2013-08-05 | Angiochem Inc | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| MX2011004017A (es) | 2008-10-15 | 2011-06-24 | Angiochem Inc | Conjugados de agonistas glp-1 y usos de los mismos. |
| BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| EP2421562B1 (en) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| CA2766537A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| WO2014026286A1 (en) * | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| US20160213760A1 (en) * | 2012-11-12 | 2016-07-28 | Angiochem Inc. | Aprotinin-derived polypeptide-antibody conjugates |
| EP2896402A1 (en) | 2014-01-20 | 2015-07-22 | Vect-Horus | Activated neurotensin molecules and the uses thereof |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| LT3393496T (lt) | 2015-12-23 | 2023-12-11 | The Johns Hopkins University | Ilgo veikimo glp-1r agonistas, kaip neurologinių ir neurodegeneracinių būklių terapija |
| CN106267231A (zh) * | 2016-08-29 | 2017-01-04 | 苏州普罗达生物科技有限公司 | 一种小分子cd19抗体多肽与环磷酰胺偶联的结合物 |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| CN110551203B (zh) * | 2019-09-25 | 2023-02-10 | 成都奥达生物科技有限公司 | 一种艾塞那肽类似物 |
| CN112079841B (zh) * | 2020-09-22 | 2022-04-26 | 武汉天马微电子有限公司 | 一种有机化合物、电致发光材料及其应用 |
| CN114187967B (zh) * | 2021-12-28 | 2024-10-29 | 大连工业大学 | 一种面向降血压肽活性的氨基酸序列预测方法 |
| WO2024192242A2 (en) * | 2023-03-14 | 2024-09-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods relating to age-related, neurological, and vascular disease conditions |
| CN120733009B (zh) * | 2025-08-29 | 2025-11-04 | 天津尤金生物科技有限公司 | 一种具有减肥功效的复合活性多肽组合物及其制备方法 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1518390A (en) | 1976-03-30 | 1978-07-19 | Farmaceutici Italia | Doxorubicin thioesters |
| US4301277A (en) | 1980-10-20 | 1981-11-17 | Sri International | 3-Deamino-3-(4-morpholinyl) derivatives of daunorubicin and doxorubicin |
| US4314054A (en) | 1981-03-23 | 1982-02-02 | Sri International | 3'-Deamino-3'-(4-methoxy-1-piperidinyl) derivatives of daunorubicin and doxorubicin |
| US4826964A (en) | 1982-07-20 | 1989-05-02 | Sri International | Bridged oxygen analogs of daunorubcin and doxorubicin |
| US4464529A (en) | 1982-07-20 | 1984-08-07 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
| US4507466A (en) | 1983-01-07 | 1985-03-26 | The Dow Chemical Corporation | Dense star polymers having core, core branches, terminal groups |
| US4585859A (en) | 1983-05-24 | 1986-04-29 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
| US4567253A (en) | 1984-02-03 | 1986-01-28 | Tony Durst | 2-Substituted derivatives of podophyllotoxin and etoposide |
| US4609644A (en) | 1984-06-15 | 1986-09-02 | St. Jude Children's Research Hospital | Epipodophyllotoxinquinone glucoside derivatives, method of production and use |
| GB2172594B (en) | 1985-03-22 | 1988-06-08 | Erba Farmitalia | New morpholino derivatives of daunorubicin and doxorubicin |
| GB8508079D0 (en) | 1985-03-28 | 1985-05-01 | Erba Farmitalia | Antitumor anthracyclines |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| IL77334A (en) | 1985-12-16 | 1991-04-15 | Univ Bar Ilan | Synthesis of 9-epipodophyllotoxin glucoside derivatives and some novel intermediates therefor |
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5527524A (en) | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
| US4876399A (en) | 1987-11-02 | 1989-10-24 | Research Corporation Technologies, Inc. | Taxols, their preparation and intermediates thereof |
| US4958010A (en) | 1988-02-16 | 1990-09-18 | Bristol-Myers Company | Epipodophyllotoxin glucoside lactam derivatives |
| US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
| US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| FR2629819B1 (fr) | 1988-04-06 | 1990-11-16 | Rhone Poulenc Sante | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii |
| FR2629818B1 (fr) | 1988-04-06 | 1990-11-16 | Centre Nat Rech Scient | Procede de preparation du taxol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| US6610299B1 (en) | 1989-10-19 | 2003-08-26 | Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
| US7241595B2 (en) | 1989-10-20 | 2007-07-10 | Sanofi-Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
| US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| US6475486B1 (en) | 1990-10-18 | 2002-11-05 | Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
| US5136060A (en) | 1989-11-14 | 1992-08-04 | Florida State University | Method for preparation of taxol using an oxazinone |
| US5015744A (en) | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
| US5304687A (en) | 1989-12-19 | 1994-04-19 | Farmitalia Carlo Erba S.R.L. | Morpholinyl derivatives of doxorubicin and process for their preparation |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5200513A (en) | 1990-06-22 | 1993-04-06 | Board Of Regents, University Of Nebraska-Lincoln | Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin |
| US5594158A (en) | 1990-06-22 | 1997-01-14 | The Board Of Regents Of The University Of Nebraska | Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin |
| GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
| US5059699A (en) | 1990-08-28 | 1991-10-22 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| FI101678B1 (fi) | 1990-12-31 | 1998-08-14 | Akzo Nv | Happolabiileja kytkentämolekyylejä |
| TW221441B (enExample) | 1991-01-25 | 1994-03-01 | Taiho Pharmaceutical Co Ltd | |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5227400A (en) | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
| US6113946A (en) | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
| IL107950A (en) | 1992-12-15 | 2001-04-30 | Upjohn Co | 7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| AU6364094A (en) | 1993-03-12 | 1994-09-26 | Board Of Regents, The University Of Texas System | Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs |
| MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
| US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
| FR2725990B1 (fr) | 1994-10-21 | 1997-01-10 | Pf Medicament | Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux |
| US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| WO1997034612A1 (en) | 1996-03-22 | 1997-09-25 | Waldemar Priebe | Bis-anthracyclines with high activity against doxorubicin resistant tumors |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| ATE366584T1 (de) | 1996-11-12 | 2007-08-15 | Novo Nordisk As | Verwendung von glp-1 peptiden |
| US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
| JP2002510193A (ja) | 1997-03-31 | 2002-04-02 | イーライ・リリー・アンド・カンパニー | グルカゴン様ペプチド−１類似体 |
| US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| US6051721A (en) | 1997-10-02 | 2000-04-18 | The Board Of Regents Of The University Of Nebraska | Ring E-modified analogues of(-)-podophyllotoxin and etoposide and a method for their synthesis |
| BR9813930A (pt) * | 1997-11-06 | 2006-12-19 | Chiron Spa | antìgeno neisserial |
| US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
| US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| EP1100530B1 (en) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In-vitro stimulation of beta cell proliferation |
| MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| US6927214B1 (en) | 1999-01-15 | 2005-08-09 | Novo Nordisk A/S | Non-peptide GLP-1 agonists |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| EP1246638B2 (en) | 2000-01-10 | 2014-07-30 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of hypertriglyceridemia |
| DE60111352T2 (de) | 2000-01-20 | 2006-05-04 | Supratek Pharma, Inc., Montreal | Podophyllotoxin-zusammensetzungen |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| US20030134420A1 (en) | 2000-02-18 | 2003-07-17 | Lollo Charles Peter | Methods and compositions for gene delivery |
| WO2001064742A1 (en) | 2000-02-29 | 2001-09-07 | Sumitomo Pharmaceuticals Company, Limited | Modified bdnf |
| EP1267912A2 (en) | 2000-03-14 | 2003-01-02 | Burkhard Göke | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| IL142707A0 (en) | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| CN103356996A (zh) | 2000-05-19 | 2013-10-23 | 埃米林药品公司 | Glp-1用于制备治疗急性冠脉综合征的药物的用途 |
| IL153453A0 (en) | 2000-06-16 | 2003-07-06 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
| FR2810321B1 (fr) | 2000-06-20 | 2002-07-26 | Adir | Nouveaux derives de podophyllotoxine carbamate et thiocarbamate, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0015444D0 (en) | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US20030027151A1 (en) * | 2000-08-18 | 2003-02-06 | Warman Matthew L. | Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| EP1313767A2 (en) | 2000-08-24 | 2003-05-28 | Thomas Jefferson University | Peptide with effects on cerebral health |
| DE60142351D1 (de) | 2000-10-20 | 2010-07-22 | Amylin Pharmaceuticals Inc | Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid |
| DE60123105T2 (de) | 2000-11-20 | 2007-04-26 | Kim, Song Bae | Verfahren zur Herstellung von 4'-O-substituierten 4'-Demethyl-1 desoxypodophyllotoxinderivaten und geometrischen Isomeren davon ,und Antikrebspräparat, das diese enthält |
| SK288342B6 (en) | 2000-12-07 | 2016-03-01 | Lilly Co Eli | GLP-1 fusion proteins |
| MXPA03005135A (es) | 2000-12-13 | 2003-12-04 | Lilly Co Eli | Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon. |
| PL362411A1 (en) | 2001-02-06 | 2004-11-02 | Merck Patent Gmbh | Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity |
| US20070249651A1 (en) | 2001-06-20 | 2007-10-25 | Nerviano Medical Sciences S.R.I. | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors |
| JP4227894B2 (ja) | 2001-08-23 | 2009-02-18 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド１アナログ |
| BR0212620A (pt) | 2001-10-01 | 2005-09-20 | Lilly Co Eli | Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1 |
| CA2463914A1 (en) | 2001-10-18 | 2003-04-24 | Ixion Biotechnology, Inc. | Conversion of liver stem and progenitor cells to pancreatic functional cells |
| JP2005514337A (ja) | 2001-10-18 | 2005-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ヒトグルカゴン様ペプチド−１模倣体、並びに糖尿病および関連疾患の処置におけるその使用 |
| US7261875B2 (en) | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| US20030199445A1 (en) | 2002-02-07 | 2003-10-23 | Knudsen Lotte Bjerre | Use of GLP-1 compound for treatment of critically ill patients |
| ATE301660T1 (de) | 2002-03-28 | 2005-08-15 | Council Scient Ind Res | Analoge von 4-beta-1''-((2''-(substitutierte- benzoyl)anilin)-podophyllotoxin zur verwendung als antikrebs-agentia |
| US7176236B2 (en) | 2002-06-21 | 2007-02-13 | University Of North Carolina At Chapel Hill | Water-soluble etoposide analogs and methods of use thereof |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| US20040209803A1 (en) | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
| EP2260874A1 (en) * | 2003-01-06 | 2010-12-15 | Angiochem Inc. | Aprotinin analogs as carriers across the blood-brain barrier |
| CA2513072A1 (en) | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| US7342114B2 (en) | 2003-07-01 | 2008-03-11 | California Pacific Medical Center | Podophyllotoxin derivatives |
| FR2859208B1 (fr) | 2003-09-02 | 2006-01-21 | Servier Lab | Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20060258576A1 (en) | 2003-09-05 | 2006-11-16 | Licentia, Ltd | Gdnf-related neuropeptides |
| JP5175108B2 (ja) | 2005-02-18 | 2013-04-03 | アンジオケム・インコーポレーテッド | 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド |
| CN100429227C (zh) | 2005-06-29 | 2008-10-29 | 常州制药厂有限公司 | Exendin4多肽片段 |
| DK2233156T3 (da) | 2005-07-15 | 2013-08-05 | Angiochem Inc | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
| US8414926B1 (en) | 2006-09-12 | 2013-04-09 | University Of South Florida | Nanoparticles with covalently bound surfactant for drug delivery |
| WO2008069876A2 (en) | 2006-10-27 | 2008-06-12 | University Of Kentucky Research Foundation | Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation |
| US20090069230A1 (en) | 2007-02-12 | 2009-03-12 | The Research Foundation Of State University Of New York | Gdnf-derived peptides |
| AU2008255556B2 (en) | 2007-05-29 | 2014-08-07 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| ES2488668T3 (es) * | 2007-05-29 | 2014-08-28 | Angiochem Inc. | Polipéptidos de tipo aprotinina para administrar agentes conjugados con los mismos a tejidos |
| FI20070808A0 (fi) | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
| EP2235175A4 (en) | 2007-12-20 | 2012-04-25 | Angiochem Inc | POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF |
| BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
| US20120196803A1 (en) * | 2009-06-11 | 2012-08-02 | Angiochem Inc. | Fusion proteins for delivery of gdnf and bdnf to the central nervous system |
| WO2011153642A1 (en) * | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
-
2011
- 2011-07-04 EP EP11800042.1A patent/EP2588490B1/en not_active Not-in-force
- 2011-07-04 MX MX2013000250A patent/MX2013000250A/es not_active Application Discontinuation
- 2011-07-04 AU AU2011274229A patent/AU2011274229A1/en not_active Abandoned
- 2011-07-04 CA CA2803646A patent/CA2803646A1/en not_active Abandoned
- 2011-07-04 BR BR112012033295A patent/BR112012033295A2/pt not_active IP Right Cessation
- 2011-07-04 CN CN2011800412044A patent/CN103080125A/zh active Pending
- 2011-07-04 WO PCT/CA2011/050408 patent/WO2012000118A1/en not_active Ceased
- 2011-07-04 JP JP2013516932A patent/JP2013530993A/ja active Pending
- 2011-07-04 RU RU2013103763/10A patent/RU2013103763A/ru not_active Application Discontinuation
-
2015
- 2015-10-23 US US14/921,584 patent/US20160263236A1/en not_active Abandoned
-
2017
- 2017-02-22 US US15/439,526 patent/US20180015180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530993A5 (enExample) | ||
| RU2013103763A (ru) | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения | |
| US10421784B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| KR101617790B1 (ko) | 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물 | |
| AU2019218786B2 (en) | Cell-permeable stapled peptide modules for cellular delivery | |
| US10118944B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| CN104684576B (zh) | 聚乙二醇化的oxm变体 | |
| US12296018B2 (en) | Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same | |
| CN108078958B (zh) | 一种抗肿瘤多肽纳米药物及其制备方法和应用 | |
| JP2012529891A5 (enExample) | ||
| JP6876618B2 (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
| CN108135881A (zh) | 多配体药物偶联体及其用途 | |
| CN104940949A (zh) | 一种抗肿瘤多肽纳米药物及其制备方法和应用 | |
| CN115151556A (zh) | 人转铁蛋白受体结合肽 | |
| Stefanick et al. | Improved peptide-targeted liposome design through optimized peptide hydrophilicity, ethylene glycol linker length, and peptide density | |
| CA3181300A1 (en) | Glp1r agonist nmdar antagonist conjugates | |
| CN107847546A (zh) | 聚乙二醇化的胃泌酸调节素变体 | |
| JP2025124693A (ja) | 中枢神経系への細胞特異的輸送のための二重標的化 | |
| CN106163569A (zh) | 活化的神经降压素分子及其用途 | |
| JP7179855B2 (ja) | 低ｐＨ挿入ペプチド及びその組成物 | |
| Sun et al. | Cytotoxic conjugates of peptide hormones for cancer chemotherapy | |
| CN111511917A (zh) | 肽结合物 | |
| EP4389758A1 (en) | Human transferrin receptor?binding peptide | |
| CN113039194A (zh) | 具有免疫调节特性的肽 | |
| AU2021368859A9 (en) | Peptide-based delivery of agents |